CRMDCorMedix Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−27% a year). The price bakes in little to no growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CRMD's price assumes
CorMedix Inc. trades at 3.57× earnings against 18.6× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 18.6 · cheaper than the typical name in its group
- Free cash flow yield
- 44%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- −27%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Healthcare median P/E509 names
- 26.0
- Biotechnology median P/E244 names
- 18.6
- Free cash flow, trailing twelve months
- $250M
- Market capitalisation
- $573M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.